Cost-Effectiveness of Comprehensive Quadruple Therapy for Heart Failure With Reduced Ejection Fraction
- 1 March 2023
- journal article
- research article
- Published by Elsevier in JACC: Heart Failure
- Vol. 11 (5) , 541-551
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Importance of Clinical Worsening of Heart Failure Treated in the Outpatient SettingCirculation, 2016
- Estimating the Long-Term Treatment Benefits of Sacubitril–ValsartanNew England Journal of Medicine, 2015
- Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter-Defibrillator Among Patients With Mild Heart FailureAnnals of Internal Medicine, 2015
- Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart FailureCirculation, 2015
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance MeasuresJACC, 2014
- Forecasting the Impact of Heart Failure in the United StatesCirculation: Heart Failure, 2013
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- Epidemiology and risk profile of heart failureNature Reviews Cardiology, 2010
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999